METHOD OF PREVENTING ADVERSE EFFECTS BY GLP-1

An inhalable dry powder formulation comprising a therapeutically effective amount of a glucagon-like peptide-1 (GLP-1) for prandial use in combination with insulin for the treatment of hyperglycemia and/or diabetes in a patient. The inhalable dry powder formulation preferably comprises a diketopiper...

Full description

Saved in:
Bibliographic Details
Main Authors COSTELLO DONALD, BAUGHMAN ROBERT A, RICHARDSON PETER
Format Patent
LanguageEnglish
Korean
Published 24.08.2010
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:An inhalable dry powder formulation comprising a therapeutically effective amount of a glucagon-like peptide-1 (GLP-1) for prandial use in combination with insulin for the treatment of hyperglycemia and/or diabetes in a patient. The inhalable dry powder formulation preferably comprises a diketopiperazine having the formula 2,5-diketo-3,6-di(4-X-aminobutyl)piperazine and wherein X is selected from the group consisting of succinyl, glutaryl, maleyl, and fumaryl, or a pharmaceutically acceptable salt thereof. The GLP-1 may be selected from the group consisting of native GLP-1, a GLP-1 metabolite, a GLP-1 analog, a GLP-1 derivative, a GLP-1 mimetic, an exendin, a GLP-1 peptide analog, a biosynthetic GLP-1 analog, or combinations thereof.
Bibliography:Application Number: KR20107011096